NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free TRVI Stock Alerts $2.76 -0.15 (-5.15%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$2.70▼$3.0350-Day Range$2.54▼$3.7052-Week Range$0.97▼$4.00Volume223,160 shsAverage Volume252,676 shsMarket Capitalization$194.74 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Trevi Therapeutics alerts: Email Address Trevi Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside207.4% Upside$8.50 Price TargetShort InterestHealthy1.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 16 Articles This WeekInsider TradingSelling Shares$13,276 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.42) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 starsMedical Sector478th out of 928 stocksPharmaceutical Preparations Industry221st out of 431 stocks 3.5 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Trevi Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.49% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 16.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVI. Previous Next 1.8 News and Social Media Coverage News SentimentTrevi Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Trevi Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,276.00 in company stock.Percentage Held by Insiders27.46% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.42) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressThe most important AI company you've never heard ofBecause this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.Get the full story on this secret AI company poised for massive growth About Trevi Therapeutics Stock (NASDAQ:TRVI)Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Read More TRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVI Stock News HeadlinesMay 15 at 8:43 AM | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,578 Shares of StockMay 13 at 6:59 PM | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call TranscriptMay 13 at 1:59 PM | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call TranscriptMay 12 at 8:53 PM | uk.investing.comEarnings call: Trevi Therapeutics reports progress in clinical trialsMay 12 at 3:57 AM | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLCMay 12 at 2:54 AM | americanbankingnews.comBrokers Issue Forecasts for Trevi Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TRVI)May 12 at 2:06 AM | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 11, 2024 | americanbankingnews.comLeerink Partnrs Comments on Trevi Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TRVI)May 9, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming ConferencesMay 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)May 8, 2024 | finance.yahoo.comQ1 2024 Trevi Therapeutics Inc Earnings CallMay 7, 2024 | investorplace.comTRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comTrevi Therapeutics Reports Q1 2024 Financial Results: A Detailed AnalysisMay 7, 2024 | prnewswire.comTrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 5, 2024 | americanbankingnews.comTrevi Therapeutics (TRVI) Set to Release Earnings on TuesdayMay 1, 2024 | yahoo.comGloria Trevi Clears First Hurdle for Lawsuit Claiming She Was Main Victim of Sex AbuseMay 1, 2024 | prnewswire.comTrevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024April 9, 2024 | finance.yahoo.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 9, 2024 | prnewswire.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 4, 2024 | uk.investing.comTrevi Therapeutics appoints new VP for clinical developmentApril 4, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming April EventsApril 2, 2024 | finance.yahoo.comTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership TeamMarch 29, 2024 | msn.comTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itMarch 28, 2024 | msn.comTrevi Italian Restaurant at Forum Shops unexpectedly closesMarch 27, 2024 | msn.comProminent Trevi Italian Restaurant Abruptly Closes at the Forum ShopsSee More Headlines Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRVI CUSIPN/A CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$9.00 Low Stock Price Target$8.00 Potential Upside/Downside+207.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.54% Return on Assets-36.80% Debt Debt-to-Equity RatioN/A Current Ratio14.55 Quick Ratio14.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.03 per share Price / Book2.68Miscellaneous Outstanding Shares70,430,000Free Float51,094,000Market Cap$194.74 million OptionableOptionable Beta0.91 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Jennifer L. Good (Age 59)Co-Founder, CEO, President & Director Comp: $781.85kDr. Thomas R. Sciascia M.D. (Age 71)Co-Founder & Chief Science Officer Comp: $530.48kDr. David J. Clark A.F.P.M. (Age 59)M.D., M.R.C.P., Chief Medical Officer Comp: $325.39kMs. Lisa Delfini (Age 54)Chief Financial Officer Mr. Christopher Galletta (Age 46)Controller & Chief Accounting Officer Katie McManusCommunications ManagerMr. Farrell Simon Pharm.D.Chief Commercial OfficerMs. Danine Summers (Age 66)Vice President of Medical Affairs More ExecutivesKey CompetitorsConduit PharmaceuticalsNASDAQ:CDTZevra TherapeuticsNASDAQ:ZVRAWerewolf TherapeuticsNASDAQ:HOWLVeruNASDAQ:VERUIncannex HealthcareNASDAQ:IXHLView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDBought 13,561 shares on 5/15/2024Ownership: 0.019%Propel Bio Management LLCBought 260,000 shares on 5/14/2024Ownership: 0.369%Vanguard Group Inc.Bought 60,249 shares on 5/10/2024Ownership: 3.271%Jennifer L GoodSold 4,578 sharesTotal: $13,276.20 ($2.90/share)Oppenheimer & Co. Inc.Bought 60,415 shares on 5/7/2024Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions TRVI Stock Analysis - Frequently Asked Questions Should I buy or sell Trevi Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVI shares. View TRVI analyst ratings or view top-rated stocks. What is Trevi Therapeutics' stock price target for 2024? 2 brokers have issued 12 month price targets for Trevi Therapeutics' stock. Their TRVI share price targets range from $8.00 to $9.00. On average, they predict the company's share price to reach $8.50 in the next year. This suggests a possible upside of 207.4% from the stock's current price. View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts. How have TRVI shares performed in 2024? Trevi Therapeutics' stock was trading at $1.34 at the beginning of 2024. Since then, TRVI stock has increased by 106.3% and is now trading at $2.7650. View the best growth stocks for 2024 here. When is Trevi Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our TRVI earnings forecast. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. What ETF holds Trevi Therapeutics' stock? Simplify Propel Opportunities ETF holds 200,000 shares of TRVI stock, representing 0.60% of its portfolio. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX). When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Trevi Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.27%), Rosalind Advisors Inc. (1.34%), Propel Bio Management LLC (0.37%), Oppenheimer & Co. Inc. (0.09%), BNP Paribas Financial Markets (0.03%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Jennifer L Good, Lisa Delfini, Paul Edward Walker and Tpg Gp A, Llc. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRVI) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.